As shown in Fig. 4, patients with higher levels of FBXL7 displayed a worse overall survival in various cancers, including colon adenocarcinoma, rectum adenocarcinoma, stomach cancer, head and neck cancer, liver cancer, thyroid cancer, lung cancer, and urothelial cancer, but better survival only in kidney renal clear cell carcinoma, implying the oncogenic characteristics of FBXL7. Here, FBXL7 is linked to lung carcinoma.